Stratatech Corporation is a pioneering force in the field of regenerative medicine. The company specializes in the development and commercialization of cell-based and tissue-engineered skin substitute products, catering to therapeutic and research applications. Notably, Stratatech Corporation has gained recognition for its innovative use of NIKS keratinocytes and their derived cells in creating human tissue substitutes for biological treatments. The company's product portfolio includes StrataGraft, a temporary wound cover that facilitates the patient’s natural cell regeneration and enhances the wound bed for autografts, and ExpressGraft, a genetically enhanced tissue capable of producing natural wound healing and antimicrobial factors. Since its establishment in 2000, Stratatech Corporation has been based in Madison, Wisconsin.
For Stratatech Corporation, the most recent investment amounting to $26.00M was secured through a grant investment on 16 October 2018. The identity of the specific investors involved in this funding round is not disclosed.
The company operates within the Biotechnology and Pharmaceutical sectors, harnessing innovative technologies to drive advancements in skin tissue engineering and regenerative medicine.
